A new study to be presented at the SLEEP 2026 annual meeting found that women with moderate-to-severe obstructive sleep apnea ...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity ...

Eli Lilly and its rivals, including Denmark's Novo Nordisk, are in a race to dominate the booming market for obesity and ...

Athens-Limestone Hospital introduces the FDA-approved Genio system to North Alabama, offering innovative nerve stimulation ...

A new sleep apnea pill reduced symptoms by 44 per cent in trials, offering hope for patients struggling with uncomfortable ...

A study found quetiapine reduced obstructive sleep apnea events but tripled attention lapses and impaired driving the next ...

A new study to be presented at the SLEEP 2026 annual meeting found that patients at high risk for obstructive sleep apnea who ...

Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Scientists reveal surprising new treatment. Sulthiame significantly reduced breathing problems in moderate to severe sleep apnea patients. Higher doses led to nearly 50% fewer breathing pauses and ...

In a Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity ...

Please provide your email address to receive an email when new articles are posted on . Researchers found heightened odds for mortality among veterans with no sleep apnea vs. with mild to moderate ...

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced ...